EXCELLENT ERADICATION RATE OF ONCE-DAILY VONOPRAZAN LEVOFLOXACIN-BASED QUADRUPLE THERAPY FOR H. PYLORI INFECTION IN HIGH CLARITHROMYCIN RESISTANCE AREA: A PROSPECTIVE RANDOMIZED STUDY

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240809001

Enrollment

100

Registered

2024-08-09

Start date

2022-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non ulcer dyspepsia with Helicobacter pylori infection Non-ulcer dyspepsia, H. pylori infection

Interventions

7-day once-daily regimens composed of vonoprazan 40 mg, clarithromycin-MR 1 g, levofloxacin 500 mg, and bismuth subsalicylate 1,048 mg,14-day once-daily regimens composed of vonoprazan 40 mg, clarithr

Active Comparator Drug,Experimental Drug

7-day regimen,14-day regimen

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Dyspeptic patient

Exclusion criteria

Exclusion criteria: 1.Upper GI hemorrhage 2.History of antibiotics use shorter than 1 month 3.History of coagulopathy 4.History of drug allergy against drug regimen 5.History of previous H. pylori infection 6.Hospice patient

Design outcomes

Primary

Measure	Time frame
Helicobactor pylori eradication rate 6 weeks Urea Breath Test	—

Secondary

Measure	Time frame
Adverse event 6 weeks Patient report	—

Countries

Thailand

Contacts

Public ContactSaran Sukkamolsantiporn

Thammasat University

saransuk@outlook.com0813463125

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026